Relationship between AKT Activation and Gefitinib Resistance in Non-small Cell Lung Adenocarcinoma
YANG Hui
JIANG Wenjuan
XIE Weibin
DING Dan
Abstract：Objective To investigate the correlation between serine-threonine protein kinase B(AKT)activation and Gefitinib resistance in non-small cell lung adenocarcinoma.Methods A total of 100 patients with non-small cell lung adeno-carcinoma treated with Gefitinib from May 2020 to May 2022 were selected as the research subjects.According to whether Ge-fitinib resistance occurred,they were divided into drug resistance group(n =42)and non-drug resistance group(n =58).The expression of AKT protein in two groups of cancer tissues was compared.Multivariate Logistic regression analysis was used to investigate the influencing factors of Gefitinib resistance.The expression of AKT protein in patients with different clinico-pathological characteristics in drug resistance group was compared,and its correlation with clinicopathological characteristics was analyzed.The predictive efficacy of different influencing factors on Gefitinib resistance was evaluated by receiver operating characteristic(ROC)curve.Results The expression level of AKT protein in drug resistance group was higher than that in non-drug resistance group(P<0.05).Smoking history,clinical stage,lymph node metastasis and AKT expression level were independent risk factors for Gefitinib resistance in non-small cell lung adenocarcinoma patients(P<0.01).There were signif-icant differences in the expression level of AKT in patients with different clinical stages and lymph node metastasis(P<0.01).In the drug resistance group,AKT expression was positively correlated with clinical stage and lymph node metastasis(P<0.01).The area under the ROC curve(0.788)of AKT expression in predicting Gefitinib resistance in patients with non-small cell lung adenocarcinoma was larger than that of smoking history(0.697),clinical stage(0.654),and lymph node metastasis(0.640),respectively(P<0.05,P<0.01).Conclusion AKT is activated in patients with non-small cell lung adenocarcinoma resistant to Gefitinib,and is closely related to clinical stage and lymph node metastasis,which has a certain predictive value for Gefitinib resistance.
Keywords：Carcinomanon-small-cell lungAdenocarcinomaGefitinibDrug resistanceneoplasmSerine-threonine protein kinase BLymph node metastasisRisk factorsPrediction
Publication Date：2023-12-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 319-324 )